OBJECTIVES: Prognostic risk factors influencing survival in patients with epithelial ovarian cancer (EOC) include tumor stage, grade, histologic subtype, debulking, and platinum status. Little is known about the impact of hormonal milieu and reproductive factors before cancer diagnosis on clinical outcome. We sought to evaluate whether oral contraceptive (OC) use carries any prognostic significance on overall survival (OS) in patients with EOC. METHODS: Newly diagnosed patients with EOC, fallopian tube, and primary peritoneal cancers between 1982 and 1998 were prospectively evaluated with a comprehensive epidemiologic questionnaire. A retrospective chart review was performed to abstract clinicopathologic data, including OS. A Kaplan-Meier analysis was performed to compare survival across various exposures. A Cox regression model was used to compute adjusted hazards ratios (aHRs) and 95% confidence intervals (CIs). RESULTS: We identified 387 newly diagnosed cancers with evaluable information in this cohort. Decreased risk of death was observed in women who reported prior use of OC (aHR, 0.79; 95% CI, 0.58-1.09), previous pregnancy (aHR, 0.77; 95% CI, 0.57-1.04), or a live birth (aHR, 0.81; 95% CI, 0.60-1.08) after adjusting for age at diagnosis, stage, and histologic subtype. Oral contraceptive use was associated with a crude reduced risk of death (HR, 0.55; 95% CI, 0.42-0.72), with reported median OS of 81 months in OC users versus 46 months in nonusers. Patients who reported a single live birth experienced the largest potential survival advantage (aHR, 0.61; 95% CI, 0.39-0.94). Oral contraceptive use and prior pregnancy were associated with improved survival across all strata. CONCLUSIONS: Oral contraceptive use may have lasting effects on epithelial ovarian tumor characteristics conferring favorable prognosis. Putative mechanisms that affect tumor biology include complex interactions between ovarian cells, host immune cells, and hormonal microenvironment during carcinogenesis. Future efforts should be directed to determine the role of reproductive factors in antitumor immunity.
OBJECTIVES: Prognostic risk factors influencing survival in patients with epithelial ovarian cancer (EOC) include tumor stage, grade, histologic subtype, debulking, and platinum status. Little is known about the impact of hormonal milieu and reproductive factors before cancer diagnosis on clinical outcome. We sought to evaluate whether oral contraceptive (OC) use carries any prognostic significance on overall survival (OS) in patients with EOC. METHODS: Newly diagnosed patients with EOC, fallopian tube, and primary peritoneal cancers between 1982 and 1998 were prospectively evaluated with a comprehensive epidemiologic questionnaire. A retrospective chart review was performed to abstract clinicopathologic data, including OS. A Kaplan-Meier analysis was performed to compare survival across various exposures. A Cox regression model was used to compute adjusted hazards ratios (aHRs) and 95% confidence intervals (CIs). RESULTS: We identified 387 newly diagnosed cancers with evaluable information in this cohort. Decreased risk of death was observed in women who reported prior use of OC (aHR, 0.79; 95% CI, 0.58-1.09), previous pregnancy (aHR, 0.77; 95% CI, 0.57-1.04), or a live birth (aHR, 0.81; 95% CI, 0.60-1.08) after adjusting for age at diagnosis, stage, and histologic subtype. Oral contraceptive use was associated with a crude reduced risk of death (HR, 0.55; 95% CI, 0.42-0.72), with reported median OS of 81 months in OC users versus 46 months in nonusers. Patients who reported a single live birth experienced the largest potential survival advantage (aHR, 0.61; 95% CI, 0.39-0.94). Oral contraceptive use and prior pregnancy were associated with improved survival across all strata. CONCLUSIONS: Oral contraceptive use may have lasting effects on epithelial ovarian tumor characteristics conferring favorable prognosis. Putative mechanisms that affect tumor biology include complex interactions between ovarian cells, host immune cells, and hormonal microenvironment during carcinogenesis. Future efforts should be directed to determine the role of reproductive factors in antitumor immunity.
Authors: K B Moysich; C Mettlin; M S Piver; N Natarajan; R J Menezes; H Swede Journal: Cancer Epidemiol Biomarkers Prev Date: 2001-08 Impact factor: 4.254
Authors: Daniel W Cramer; Linda Titus-Ernstoff; John R McKolanis; William R Welch; Allison F Vitonis; Ross S Berkowitz; Olivera J Finn Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-05 Impact factor: 4.254
Authors: J A Baker; O O Odunuga; K J Rodabaugh; M E Reid; R J Menezes; K B Moysich Journal: Int J Gynecol Cancer Date: 2006 Jan-Feb Impact factor: 3.437
Authors: James Brian Szender; Rikki Cannioto; Nicolas R Gulati; Kristina L Schmitt; Grace Friel; Albina Minlikeeva; Alexis Platek; Emily H Gower; Ryan Nagy; Edgar Khachatryan; Paul C Mayor; Karin A Kasza; Shashikant B Lele; Kunle Odunsi; Kirsten B Moysich Journal: J Low Genit Tract Dis Date: 2016-07 Impact factor: 1.925
Authors: Rikki Cannioto; John Lewis Etter; Lauren Beryl Guterman; Janine M Joseph; Nicholas R Gulati; Kristina L Schmitt; Michael J LaMonte; Ryan Nagy; Albina Minlikeeva; James Brian Szender; Kirsten B Moysich Journal: Cancer Epidemiol Date: 2017-05-18 Impact factor: 2.984
Authors: Minh Tung Phung; Aliya Alimujiang; Andrew Berchuck; Hoda Anton-Culver; Joellen M Schildkraut; Elisa V Bandera; Jenny Chang-Claude; Anne Chase; Jennifer Anne Doherty; Bronwyn Grout; Marc T Goodman; Gillian E Hanley; Alice W Lee; Cindy McKinnon Deurloo; Usha Menon; Francesmary Modugno; Paul D P Pharoah; Malcolm C Pike; Jean Richardson; Harvey A Risch; Weiva Sieh; Kathryn L Terry; Penelope M Webb; Nicolas Wentzensen; Anna H Wu; Celeste Leigh Pearce Journal: Cancer Epidemiol Biomarkers Prev Date: 2022-04-01 Impact factor: 4.090
Authors: Rikki Cannioto; John Lewis Etter; Michael J LaMonte; Andrew D Ray; Janine M Joseph; Emad Al Qassim; Kevin H Eng; Kirsten B Moysich Journal: Cancer Treat Res Commun Date: 2018